Gold investors remain bullish amid tariff scramble
Why it matters: The snip-snap approach to tariffs roiled bullion prices, but investors say they are bullish with or without the tariffs.
Catch up quick: Switzerland is one of the largest gold refiners in the world, exporting over $50 billion worth over the 12 months ending in June.
Gold exports spiked early this year as investors sought to frontload tariffs, according to HSBC.
What they're saying:"This action further bolsters our bullish outlook for gold prices, with these tariffs set to disrupt the flow of gold globally and push both the US and global price higher," Trevor Yates, senior investment analyst at Global X, wrote in a note.
Between the lines: There are still several catalysts ahead for gold demand, according to Bob Iaccino, chief market strategist at Path Trading Partners and author of the Finance Unfiltered newsletter.
Volatility amid tariff uncertainty would be good for gold, since it is still considered a safe haven asset. Rate cuts could be another tailwind.
Central bank purchases of gold also continue to climb amid a de-dollarization push driven by tariff policy by the administration.
Zoom out: Investors have been riding the gold gravy train all year, according to the latest Gold Demand Trends report from the World Gold Council.
Gold ETF inflows hit 170 metric tons in the second quarter of 2025, valued at nearly $400 billion, the strongest first half finish since 2020.
Retail investment rose 11% year-over-year, driven by demand in China.
Central banks added 166 metric tons in the second quarter, with 95% of reserve managers expecting central bank buying to keep exacerbating.
Yes, but: There remains uncertainty about what reciprocal tariffs on other gold-exporting countries could mean for the precious metal.
The only two countries the U.S. gets more gold from than Switzerland are Canada and Mexico.
Be smart: According to Bloomberg, managers at gold refineries are already pausing shipments until there is more clarity on levies.
Tariffs could also have severe implications for how gold futures are traded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
6 hours ago
- New York Times
Behind Wall Street's Abrupt Flip on Crypto
Not long ago, bank executives would compete with one another to be the loudest critic of cryptocurrencies. Jamie Dimon, the chief executive of JPMorgan Chase, once compared Bitcoin to a pet rock and said the whole crypto industry should be banned. Bank of America's Brian Moynihan described the space as an 'untraceable tool for money laundering,' while HSBC's chief executive proclaimed bluntly: 'We are not into Bitcoin.' Now big banks can't stop talking about crypto. In investor calls, public presentations and meetings with Washington regulators, financial executives are tripping over one another to unveil new plans — including the development of fresh cryptocurrencies under bank umbrellas and loans tied to digital assets. There's no small mix of political opportunism at play, given that President Trump and his family are vociferous crypto boosters and investors. And of course there is a degree of old-fashioned jealousy among the traditional finance set at the riches earned by onetime fringe companies and investors as Bitcoin more than doubled over the past year to blow past $100,000. But behind the scenes at major financial institutions — and in stark contrast to the public showboating among chief executives — fear is also rising that the rush into crypto may risk the safety of personal bank accounts in ways that Wall Street and Washington are just beginning to understand. The worries, described by nine Wall Street executives briefed on their organizations' crypto initiatives but not authorized to speak publicly for their employers, center on the creation of a new interbank checking account and payments system built on crypto and blockchain technology. That system would come with few consumer protections and nascent regulatory oversight. Want all of The Times? Subscribe.
Yahoo
6 hours ago
- Yahoo
HSBC Raises Novo Nordisk (NVO) Price Target on Oral Semaglutide Market Share Boost
Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a 'Hold' rating on Novo Nordisk and lifted the price target to 355 Danish Krone (DKK) from DKK340. HSBC increased the price target because it raised its estimates for the market share of oral semaglutide. Semaglutide is a pill that helps people with type 2 diabetes or obesity manage their condition. Novo Nordisk sells oral semaglutide for diabetes under the brand name Rybelsus. Pixabay/Public Domain HSBC projects that peak sales for the drug could exceed DKK15 billion ($2.34 billion) after 2034. The bank kept the 'Hold' rating on the stock due to 'ongoing concerns about market size' and 'overhang compounders.' The analysts identified a potential 'upside' for the stock if there is a recovery in Wegovy prescriptions in the U.S. Novo Nordisk A/S (NYSE:NVO) is a Danish global healthcare company. It develops and manufactures pharmaceutical products for chronic diseases, with a primary focus on diabetes, obesity, and rare blood and endocrine disorders. The company's portfolio includes GLP-1 therapies, such as Ozempic and Wegovy, as well as insulin and growth hormone treatments. While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Copper Stocks to Buy According to Hedge Funds and 10 Best EV Penny Stocks to Buy According to Hedge Funds. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
7 hours ago
- Yahoo
Should You Buy the Post-Earnings Dip in CoreWeave Stock?
CoreWeave (CRWV) is down nearly 20% at the time of writing even after reporting market-beating revenue for its second quarter and offering upbeat guidance for the future. The AI infrastructure company saw its revenue more than triple to $1.2 billion in Q2, but investors seem to be fixating on the looming expiration of its lockup period on Thursday, Aug. 14. More News from Barchart Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! CoreWeave stock has been on an absolute tear since its debut in late March. Even after today's dip, it's up roughly 200% versus its initial public offering (IPO) price of just $40. Why the Lockup Expiration Is Negative for CoreWeave Stock Investors are concerned that CRWV shares could sink rather significantly once the lockup period expires on Aug. 14 after market close. Why? Because the lockup period essentially refers to a set timeframe (often 90 to 180 days) during which insiders and early investors are restricted from selling a company's stock. Now that it's expiring for CoreWeave, insiders may consider trimming their stake in the AI infrastructure firm, especially since its share price has nearly quadrupled since late April. In short, if insiders and early investors do indeed choose to take profit after the lockup expires, the added supply could exert pressure on CoreWeave stock over the next few weeks. HSBC Warns of a Massive Crash in CRWV Shares HSBC analysts recommend selling the post-earnings rip in CoreWeave shares because the artificial intelligence infrastructure company lacks revenue diversification. In its research note, the investment firm said lower utilization of data center assets could materially contract CRWV margins to 60.4% in the second half of this year. Then of course, there's the valuation overhang. The AI stock is currently trading at a price-sales (P/S) ratio of about 26x, overly stretched given the Nasdaq-listed firm is yet to turn a profit. HSBC maintained its $32 price target on CRWV shares today indicating potential downside of nearly 75% from here. Wall Street Rates CoreWeave at 'Hold' Only Investors should note that other Wall Street firms are not particularly bullish on CoreWeave stock either. The consensus rating on CRWV stock currently sits at 'Hold' only with the mean target of roughly $100 suggesting potential downside of another 17% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
